Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 7/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9149193 | 0.76 | TSHR (0.55) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL5933590 | 0.74 | TSHR (0.52) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL5932563 | 0.74 | TSHR (0.52) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL5932494 | 0.74 | TSHR (0.52) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL15510573 | 0.72 | TSHR (0.50) | MAPTHSD17B10TSHRALDH1A1CYP3A4 | |
| SCHEMBL9153194 | 0.70 | TSHR (0.60) | MAPTTSHRALDH1A1 | |
| SCHEMBL5932248 | 0.70 | TSHR (0.60) | MAPTTSHRALDH1A1CYP3A4 | |
| SCHEMBL10401277 | 0.70 | TSHR (0.60) | MAPTTSHRALDH1A1CYP3A4 | |
| SCHEMBL11895181 | 0.68 | TSHR (0.57) | MAPTTSHRALDH1A1CYP3A4 | |
| SCHEMBL5932636 | 0.68 | TSHR (0.50) | TSHRALDH1A1CYP3A4HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | MAPT 2278/4885HSD17B10 173/4885TSHR 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.